Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administration

Steroids

Volumn 65, Issue 10-11, 2000, Pages 831-836

  Heikinheimoab, Oskari ^a   Ranta, Sirpa ^a   Grunberg, Steven ^b   Spitz, Irving M ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Antiprogestin; Estrogen metabolism; FSH; LH; Progesterone antagonists; Progesterone receptor modulators; SHBG

Indexed keywords

ANDROSTENEDIONE; ANTIGESTAGEN; ESTRADIOL; ESTRONE; FOLLITROPIN; GLUCOCORTICOID ANTAGONIST; GONADOTROPIN; LUTEINIZING HORMONE; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANDROSTENEDIONE BLOOD LEVEL; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; ESTRONE BLOOD LEVEL; FEMALE; FLUOROIMMUNOASSAY; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; MENINGIOMA; POSTMENOPAUSE; RADIOIMMUNOASSAY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

DRUG EVALUATION; ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; GONADOTROPINS; HUMANS; LUTEINIZING HORMONE; MIFEPRISTONE; POSTMENOPAUSE; TESTOSTERONE; TIME FACTORS;

EID: 0033652191     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(00)00196-3     Document Type: Conference Paper

References (25)

1. Regression of uterine leiomyomata in response to the antiprogesterone RU486
2. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis
3. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone
4. Antiprogestins, a new form of endocrine therapy for human breast cancer
5. The endocrine effects of long-term treatment with mifepristone (RU 486)
6. Alterations in the pituitary-thyroid and pituitary-adrenal axis-Consequences of long-term mifepristone treatment
7. The new steroid analog RU 486 inhibits glucocorticoid action in man
8. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486
9. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU486
10. Inhibition of ovulation by low-dose mifepristone (RU 486)
11. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle
12. Regression of uterine leiomyomata to the antiprogesterone RU486: Dose-response effect
13. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days
14. Role of antiprogestational therapy for meningiomas
15. Quantitation of RU486 in human plasma by HPLC and RIA after column chromatography
16. The divergent effects of RU486 on adrenal function in the dog is related to differences in its pharmacokinetics
17. Steroid dynamics under steady-state conditions
18. The biology of menopause
19. Long-term treatment with the oral antiprogestational agent mifepristone (RU486)
20. The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor
21. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women
22. Maternal serum levels of sex steroid-binding protein during pregnancy
23. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: Recent advances
24. New progestogens in oral contraception
25. Metabolism and serum binding of RU 486 in women after various single doses